About Us

Biomodels was founded in 1997 with the idea of creating a more useful interface between leading academic researchers and the pharmaceutical industry. To achieve this goal, Biomodels was set up as an independent company to establish collaborative relationships with highly regarded academic scientists, and obtain rights to use proprietary models and technologies for commercial purposes.

Biomodels provides its clients with access to selected predictive models in the areas of cancer, cancer supportive care, radiation therapy and inflammatory diseases. In addition, Biomodels is able to provide its clients with superior pre-clinical advice through a series of collaborative relationships with leading academic researchers and institutions. As a result of these collaborative relationships, Biomodels’ clients receive superior research together with the confidence of knowing their results can be relied upon to assess the potential for clinical success. Several of the world’s largest and most respected pharmaceutical companies, as well as many small and mid-size companies, regularly call on Biomodels for outsourced preclinical research.

Biomodels is committed to providing its clients with access to studies designed by the thought leaders in each field and with the ability to provide these services in a timely manner.


Biomodels Advantage

Quick Turnaround: Biomodels emphasizes speed in turnaround time; the in-life phase of a study is commonly initiated within two weeks of protocol agreement, preliminary data reports are issued within days of study completion and final reports can be expected just a couple of weeks thereafter.

Personalized Service: We view our clients as collaborators rather than customers. The result is an active engagement in personal service and scientific discussions to develop and execute your studies. At Biomodels, you will work with a PhD level scientist who is an expert in your selected disease indication and who will be your primary resource to assist in study design, monitor quality control, and provide timely updates on study progress, allowing for real time decisions that often result in improved study outcomes.

Customized Solutions: Innovative and modified animal models are often needed to keep pace with the ever-changing landscape of medicine and science. Biomodels specializes in the development of custom disease models to accommodate novel biologics and disease indications for which the current animal models are insufficient or do not exist. The result for our clients has been success in a variety of purposes including the preliminary testing of compounds in emerging (or understudied) therapeutic areas, mechanism of action studies, and the identification of novel molecular biomarkers of disease.

Translatable Models: Core to the Biomodels mission is to provide clinically relevant and highly translational models of human diseases. Providing this distinctive service at a consistently high level of quality is made possible by the unique blend of professionals comprising the Biomodels team. In addition, Biomodels has a number of long standing collaborative relationships with Clinicians who are considered experts in the clinical management of diseases associated with the models we offer. The combination of clinical and scientific skill-sets produce an efficient team with a track record of enabling over 40 novel therapeutics to move from test tube to patients.



Biomodels has earned accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) for upholding the highest standards in animal use and care.


Biomodels is compliant with all U.S. Department of Agriculture (USDA) standards.


*Biomodels is compliant with all Office of Laboratory Animal Welfare (OLAW) policies and guidelines.